Page 148 - ESHRE2019

Limitations of immunological assays
Baker, 2015
Rizner T.L. Et al.
Problems with antibodies:
 cross reactivity,
 batch to batch variations,  lack of validation. Problems with ELISA assays?
Rizner et al. 2016 31
Serum proteomics in search for biomarkers of endometriosis
Study
Method
Group
Findings
Diagnostic accuracy
Dutta et al. 2016
2DE, 2D‐ DIGE MALDI TOF‐MS
280 patients (52 I, 52 II, 53 III, 52 IV) 79 control heatlhy women, secretory phase
2DE:HP, LRG1 APOA1, CLU, C4B 2D‐DIGE:
101 protein spots p< 0.05 AFA, HP, ITIH4, IGKC, ALB, TRIM5, A1BG
stages I, II, III and IV
haptoglobulin (HP) SEN: 80‐92%
SP: 76‐96%
AUC: 0.78‐0.96
Ig  chain C region (IGKC) SEN: 68‐84%
SP: 88‐92%
AUC: 0.75‐0.93 alpha‐1‐glycoprotein (A1BG) SEN: 80‐92%
SP: 48‐80% AUC: 0.62‐0.92
32
146
143